Research & Faculty

Default Header Image

Inhibition of Chk1 by the G(2) DNA damage checkpoint inhibitor isogranulatimide

TitleInhibition of Chk1 by the G(2) DNA damage checkpoint inhibitor isogranulatimide
Publication TypeJournal Article
Year of Publication2004
AuthorsJiang, XX, Zhao, BG, Britton, R, Lim, LY, Leong, D, Sanghera, JS, Zhou, BBS, Piers, E, Andersen, RJ, Roberge, M
JournalMolecular Cancer Therapeutics
Volume3
Pagination1221-1227
Date PublishedOct
Type of ArticleArticle
ISBN Number1535-7163
Keywords7-HYDROXYSTAUROSPORINE UCN-01, ACTIVATION, CANCER, CELL-CYCLE, DEPENDENT PROTEIN-KINASE, IDENTIFICATION, MECHANISMS, PHOSPHORYLATION, SPECIFICITY, SUBSTRATE
Abstract

Inhibitors of the G(2) DNA damage checkpoint can selectively sensitize cancer cells with mutated p53 to killing by DNA-damaging agents. Isogranulatimide is a G2 checkpoint inhibitor containing a unique indole/maleimide/ imidazole skeleton identified in a phenotypic cell-based screen; however, the mechanism of action of isogranulatimide is unknown. Using natural and synthetic isogranulatimide analogues, we show that the imide nitrogen and a basic nitrogen at position 14 or 15 in the imidazole ring are important for checkpoint inhibition. Isogranulatimide shows structural resemblance to the aglycon of UCN-01, a potent bisindolemaleimide inhibitor of protein kinase Cbeta (IC50, 0.001 mumol/L) and of the checkpoint kinase Chk1 (IC50, 0.007 mumol/L). In vitro kinase assays show that isogranulatimide inhibits Chk1 (IC50, 0.1 mumol/L) but not protein kinase Cbeta. Of 13 additional protein kinases tested, isogranulatimide significantly inhibits only glycogen synthase kinase-3beta (IC50, 0.5 mumol/L). We determined the crystal structure of the Chk1 catalytic domain complexed with isogranulatimicle. Like UCN-01, isogranulatimide binds in the ATP-binding pocket of Chk1 and hydrogen bonds with the backbone carbonyl oxygen of Glu(85) and the amide nitrogen Of Cys(87). Unlike UCN-01, the basic N15 of isogranulatimide interacts with Glu(17), causing a conformation change in the kinase glycine-rich loop that may contribute importantly to inhibition. The mechanism by which isogranulatimide inhibits Chk1 and its favorable kinase selectivity profile make it a promising candidate for modulating checkpoint responses in tumors for therapeutic benefit.

URL<Go to ISI>://000224488400006